โ† Back to Study Notes

Nerves & Neuromuscular Junction

Physiology

๐Ÿ”ฌ Nerve Structure & Organization

Peripheral Nerve Anatomy

Layer Description Clinical Significance
Endoneurium Surrounds individual nerve fibers Must be intact for regeneration; contains blood-nerve barrier
Perineurium Surrounds fascicles (bundles of fibers) Main component of blood-nerve barrier; determines nerve tensile strength
Epineurium Surrounds entire nerve Contains vasa nervorum; surgical repair target

Myelination

Feature PNS (Schwann Cells) CNS (Oligodendrocytes)
Cell:Axon ratio 1 Schwann cell : 1 internode 1 oligodendrocyte : up to 50 internodes
Regeneration Good (Schwann cells guide regrowth) Poor (inhibitory environment)
Diseases GBS, CIDP, CMT MS, leukodystrophies

Nodes of Ranvier

๐Ÿ’Ž Board Pearl

Saltatory conduction allows action potentials to “jump” between nodes of Ranvier, greatly increasing conduction velocity. Demyelination exposes paranodal K+ channels โ†’ hyperpolarization โ†’ conduction failure.

โšก Nerve Fiber Classification

Erlanger-Gasser Classification (Sensory & Motor)

Fiber Type Diameter (ฮผm) Velocity (m/s) Myelination Function
Aฮฑ 12-20 70-120 Heavy Motor to skeletal muscle; proprioception (Ia, Ib)
Aฮฒ 5-12 30-70 Heavy Touch, pressure (type II)
Aฮณ 3-6 15-30 Medium Motor to muscle spindle (intrafusal)
Aฮด 2-5 12-30 Light Fast pain, temperature, touch (type III)
B 1-3 3-15 Light Preganglionic autonomic
C 0.5-1.5 0.5-2 Unmyelinated Slow pain, temperature, postganglionic autonomic (type IV)
๐Ÿ’Ž Board Pearl

Conduction velocity โ‰ˆ 6 ร— diameter (in ฮผm). Large, myelinated fibers (Aฮฑ) are affected first by compression/ischemia. Small unmyelinated fibers (C) are affected first by metabolic/toxic neuropathies (diabetes).

Clinical Correlates of Fiber Type Involvement

Fiber Type Affected Clinical Features Example Conditions
Large fiber Loss of proprioception, vibration; sensory ataxia; areflexia GBS, CIDP, B12 deficiency, Friedreich ataxia
Small fiber Burning pain, loss of pinprick/temperature; autonomic dysfunction; preserved reflexes Diabetic neuropathy (early), amyloid, Fabry disease
Motor fiber Weakness, atrophy, fasciculations ALS, MMN, lead toxicity
Autonomic fiber Orthostatic hypotension, anhidrosis, GI/GU dysfunction Diabetes, amyloid, autoimmune autonomic ganglionopathy

๐Ÿ”— Neuromuscular Junction

NMJ Anatomy

Neuromuscular Transmission Steps

  1. Action potential arrives at nerve terminal
  2. Ca2+ influx through P/Q-type voltage-gated calcium channels
  3. ACh vesicle fusion with presynaptic membrane (SNARE proteins)
  4. ACh release into synaptic cleft (quantal release)
  5. ACh binds to postsynaptic nicotinic receptors
  6. Na+ influx โ†’ end-plate potential (EPP)
  7. If EPP exceeds threshold โ†’ muscle action potential โ†’ contraction
  8. ACh hydrolysis by acetylcholinesterase

Safety Factor

Definition: EPP amplitude is normally 3-4x greater than threshold needed for muscle AP

Clinical significance:

๐Ÿ’Ž Board Pearl

P/Q-type Ca2+ channels are the target in Lambert-Eaton myasthenic syndrome. SNARE proteins (synaptobrevin, SNAP-25, syntaxin) are targeted by botulinum toxin and tetanus toxin.

โš ๏ธ Neuromuscular Junction Disorders

Comparison of Major NMJ Disorders

Feature Myasthenia Gravis Lambert-Eaton Botulism
Target Postsynaptic AChR Presynaptic P/Q Ca2+ channels Presynaptic SNARE proteins
Mechanism Antibody blocks/destroys AChR Antibody reduces Ca2+ influx โ†’ less ACh release Toxin cleaves SNAREs โ†’ blocks ACh release
Weakness pattern Ocular, bulbar, proximal; fatigable Proximal legs > arms; improves with exercise Descending: cranial โ†’ limbs โ†’ respiratory
Reflexes Normal Reduced/absent (improve post-exercise) Reduced/absent
Autonomic Usually spared Dry mouth, constipation, impotence Prominent (dilated pupils, dry mouth, ileus)
RNS pattern Decrement at low-frequency (2-3 Hz) Low baseline CMAP; increment >100% post-exercise Low baseline CMAP; small increment post-exercise
Association Thymoma (10-15%); thymic hyperplasia Small cell lung cancer (50-60%) Contaminated food, wound, infant (honey)
Myasthenia Gravis – Details โ–ผ

Antibodies:

  • AChR antibodies: 85% of generalized MG
  • MuSK antibodies: 5-8%; more bulbar, muscle atrophy
  • LRP4 antibodies: Rare; milder phenotype
  • Seronegative: ~10%

Clinical features:

  • Fatigable weakness (worse with activity, better with rest)
  • Ptosis, diplopia (ocular MG in 50% at onset)
  • Bulbar: dysarthria, dysphagia, facial weakness
  • Limb weakness (proximal > distal)

Myasthenic crisis: Respiratory failure requiring intubation; triggered by infection, surgery, medications

Drugs that worsen MG: Aminoglycosides, fluoroquinolones, beta-blockers, magnesium, neuromuscular blockers

Lambert-Eaton Myasthenic Syndrome – Details โ–ผ

Key features:

  • Proximal leg weakness โ†’ arms โ†’ bulbar (opposite of MG)
  • Facilitation: Strength improves briefly after sustained contraction
  • Autonomic symptoms prominent (dry mouth in >80%)
  • Reflexes absent but may appear after exercise

Cancer association:

  • 50-60% have small cell lung cancer (SCLC)
  • Cancer may present years after LEMS diagnosis
  • Screen with CT chest; repeat if initially negative

Treatment: 3,4-diaminopyridine (blocks K+ channels โ†’ prolongs depolarization โ†’ more Ca2+ entry)

๐Ÿ’Ž Board Pearl

MG = fatigable (gets worse with use). LEMS = facilitates (gets better with use). Both have proximal weakness. LEMS has autonomic symptoms; MG does not. Always screen LEMS for SCLC!

๐Ÿ”ง Nerve Injury & Regeneration

Seddon Classification

Type Pathology Recovery EMG/NCS
Neurapraxia Local demyelination; axon intact Complete; weeks to 3 months Conduction block; no denervation
Axonotmesis Axon disrupted; endoneurium intact Good; 1 mm/day (1 inch/month) Wallerian degeneration; fibs/PSWs; reinnervation potentials
Neurotmesis Complete nerve transection Poor; requires surgery Complete denervation; no recovery without repair

Sunderland Classification (More Detailed)

Grade Seddon Equivalent Injury Prognosis
I Neurapraxia Myelin only Excellent
II Axonotmesis Axon (endoneurium intact) Good
III Axonotmesis Axon + endoneurium Variable
IV Axonotmesis Axon + endo + perineurium Poor
V Neurotmesis Complete transection None without surgery

Wallerian Degeneration

Nerve Regeneration

๐Ÿ’Ž Board Pearl

Neurapraxia = conduction block without Wallerian degeneration. No fibrillations on EMG. Full recovery expected. In axonotmesis, fibs/PSWs appear in 2-5 weeks (earliest in proximal muscles).

๐Ÿ“Š Electrodiagnostic Correlates

Nerve Conduction Study (NCS) Basics

Parameter What It Measures Abnormal In
Amplitude Number of functioning axons Axonal loss, conduction block
Conduction velocity Speed of fastest fibers (myelination) Demyelination
Distal latency Time from distal stim to response Distal demyelination

Demyelinating vs Axonal Patterns

Feature Demyelinating Axonal
Conduction velocity Markedly slow (<70% LLN) Normal or mildly slow
Distal latency Prolonged (>130% ULN) Normal or mildly prolonged
Amplitude May be preserved (early) or low Low (proportional to axon loss)
Temporal dispersion Present Absent
Conduction block Present Absent
F-wave latency Prolonged or absent Normal or mildly prolonged
EMG fibrillations Less prominent (unless secondary axonal loss) Prominent
Examples GBS (AIDP), CIDP, CMT1 Diabetic neuropathy, AMAN, CMT2

Key EDX Findings

Conduction Block โ–ผ

Definition: >50% reduction in proximal vs distal CMAP amplitude (excluding common entrapment sites)

Significance:

  • Indicates focal demyelination
  • Axon is intact but impulse cannot pass through demyelinated segment
  • Causes weakness WITHOUT atrophy (no Wallerian degeneration)
  • Potentially reversible with remyelination

Classic conditions:

  • GBS (acute)
  • CIDP (chronic)
  • Multifocal motor neuropathy (MMN)
  • Hereditary neuropathy with liability to pressure palsies (HNPP)
Temporal Dispersion โ–ผ

Definition: Increased CMAP duration with proximal stimulation (>30% increase)

Mechanism: Different degrees of demyelination cause different conduction velocities โ†’ desynchronization of impulses

Significance: Feature of acquired demyelinating neuropathies (not seen in uniform hereditary demyelination like CMT1A)

F-Waves and H-Reflex โ–ผ

F-Wave

  • Pathway: Motor nerve โ†’ anterior horn โ†’ same motor nerve back (antidromic โ†’ orthodromic)
  • Tests: Entire motor nerve including proximal segments and roots
  • Abnormal in: Proximal demyelination (GBS), radiculopathy
  • Features: Variable latency and morphology; small amplitude

H-Reflex

  • Pathway: Ia afferent โ†’ spinal cord โ†’ alpha motor neuron โ†’ muscle (monosynaptic reflex)
  • Essentially: Electrical equivalent of ankle jerk (S1 root)
  • Tests: S1 nerve root function; only reliably obtained in tibial nerve/soleus
  • Abnormal in: S1 radiculopathy, polyneuropathy
๐Ÿ’Ž Board Pearl

Conduction block = demyelinating. Low amplitudes everywhere = axonal. Temporal dispersion indicates acquired (non-uniform) demyelination. F-waves test proximal nerve segments not accessible to routine NCS.

โšก Channelopathies

Sodium Channelopathies

Disorder Gene/Channel Mechanism Clinical Features
Hyperkalemic Periodic Paralysis SCN4A (Nav1.4) Gain of function โ†’ prolonged depolarization Attacks with high K+, fasting, rest after exercise; myotonia common
Paramyotonia Congenita SCN4A (Nav1.4) Impaired fast inactivation Cold-induced myotonia; “paradoxical” myotonia (worsens with activity)
Sodium Channel Myotonia SCN4A (Nav1.4) Delayed inactivation Myotonia without weakness; K+-aggravated

Calcium Channelopathies

Disorder Gene/Channel Mechanism Clinical Features
Hypokalemic Periodic Paralysis CACNA1S (Cav1.1) – 70%
SCN4A – 10%
Loss of function โ†’ reduced excitability Attacks with low K+, carbs, rest after exercise; NO myotonia
Malignant Hyperthermia RYR1 (ryanodine receptor) Uncontrolled Ca2+ release from SR Triggered by volatile anesthetics, succinylcholine; rigidity, hyperthermia, rhabdomyolysis

Chloride Channelopathies

Disorder Gene/Channel Clinical Features
Myotonia Congenita (Thomsen/Becker) CLCN1 (ClC-1) Myotonia (muscle stiffness); improves with activity (“warm-up”); muscle hypertrophy; NO weakness

Periodic Paralysis Comparison

Feature Hypokalemic PP Hyperkalemic PP
K+ during attack Low (<3.5) High or normal
Triggers Carbs, rest after exercise, stress Fasting, rest after exercise, cold, K+
Myotonia Absent Often present
Attack duration Hours to days Minutes to hours
Treatment K+ replacement; acetazolamide prophylaxis Carbs, inhaled ฮฒ-agonist; acetazolamide or dichlorphenamide prophylaxis
๐Ÿ’Ž Board Pearl

HypoKPP: no myotonia. HyperKPP: myotonia common. Both worsen with rest after exercise. Acetazolamide works for both (metabolic acidosis โ†’ reduced attack frequency). Malignant hyperthermia = RYR1 mutation; treat with dantrolene.

๐Ÿ“Š Summary Tables & Quick Reference

Nerve Fiber Types Quick Reference

Fiber Function Lost First In
Aฮฑ (large, myelinated) Motor, proprioception Compression, ischemia
Aฮฒ (large, myelinated) Touch, pressure Compression, ischemia
Aฮด (small, myelinated) Fast pain, temperature Metabolic (later)
C (small, unmyelinated) Slow pain, autonomic Metabolic (diabetes), toxic

NMJ Disorders – RNS Patterns

Disorder Low-Frequency RNS (2-3 Hz) Post-Exercise/High-Frequency
Myasthenia Gravis Decrement >10% Repair of decrement (post-activation facilitation)
Lambert-Eaton Low baseline; may decrement Increment >100%
Botulism Low baseline; may decrement Small increment (20-40%)

Nerve Injury – Timing of EDX Findings

Finding Timing After Injury
Reduced recruitment Immediately
Reduced SNAP/CMAP distal to lesion 7-10 days (Wallerian degeneration complete)
Fibrillations in proximal muscles 2-3 weeks
Fibrillations in distal muscles 4-5 weeks
Nascent MUPs (reinnervation) 2-4 months (depends on distance)

Key Clinical Pearls

๐Ÿ” High-Yield Points
  • Velocity โ‰ˆ 6 ร— diameter: Large fibers conduct faster
  • Demyelinating = slow velocity, conduction block, temporal dispersion
  • Axonal = low amplitude, fibrillations on EMG
  • MG fatigues; LEMS facilitates
  • Neurapraxia: Best prognosis, conduction block, no fibs
  • Regeneration rate: 1 mm/day (1 inch/month)
  • F-waves: Test proximal nerve; prolonged in GBS
  • Always screen LEMS for small cell lung cancer

Red Flags

โš ๏ธ Urgent Situations
  • Respiratory muscle weakness in MG: Check FVC; <15-20 mL/kg = intubate
  • Rapidly progressive weakness with areflexia: GBS – monitor respiratory function
  • Descending paralysis with autonomic symptoms: Botulism – antitoxin urgently
  • New-onset LEMS: Search for SCLC (may precede cancer by years)
  • Malignant hyperthermia: Stop anesthesia, give dantrolene, cool patient
โ†‘